Back to results
US 2009/0022759 A1Published application
Adenovirus vector and method to manipulate the adenovirus genome
OwnerHans Gerhard Burgert, Ruzsics Zsoltinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerHans Gerhard Burgert, Ruzsics Zsoltinventors
Estimating the term…
Adenoviruses (Ads) and vectors derived thereof have been used for somatic gene therapy, gene therapy of cancer and gene therapy of infectious diseases/vaccination. To date, almost all trials are based on the well established Ad5-based vectors. Pre-existing immunity and the limited targeting specificity of Ad5 makes it desirable to exploit new Ad serotypes for these therapeutic avenues. This is hampered by the limited number of cloned Ad genomes and the difficulty to manipulate them genetically. We describe an isolated adenovirus, and/or a variant adenovirus that is optionally modified to include a heterologous nucleic acid molecule and pharmaceutical compositions comprising said adenovirus. This adenovirus has a lower pre-existing immunity and exhibits interesting targeting activities for a variety of tissues and cells, and may be particularly useful for transduction of dendritic cells and other leukocytes and or leukocyte based tumours. We also describe new methods to clone and manipulate adenoviral genomes.
An isolated adenovirus, wherein the genome of said adenovirus comprises the nucleic acid sequence shown in FIG. 2, or a variant adenovirus wherein said variant adenovirus genome is modified by the addition, deletion or substitution of at least one nucleotide base and hybridises under stringent hybridization conditions to the nucleic acid molecule shown in FIG. 2.
(canceled)
(canceled)
14-18. (canceled)
20-26. (canceled)
(canceled)
33-39. (canceled)
41-44. (canceled)
46-66. (canceled)
(canceled)
(canceled)
(canceled)
A chimeric adenovirus comprising a first nucleic acid encoding an adenovirus 19a fiber or modified fiber polypeptide or part thereof and at least one second nucleic acid comprising an adenovirus nucleic acid not derived from a Ad19a serotype.
76-100. (canceled)
A method of infecting a cell with an adenovirus, wherein said cell expresses low levels, or does not express detectable levels, of coxsackie adenovirus receptor, comprising exposing said cell to an adenovirus comprising a fiber of a subgenus D adenovirus, wherein said virus is capable of infecting said cell.
The method of transducing a cell with a gene of interest, wherein said cell expresses low levels, or does not express detectable levels, of cell surface coxsackie adenovirus receptor, comprising exposing said cell to an adenovirus comprising a fiber of a subgenus D adenovirus, or part thereof, such that said virus is capable of infecting said cell, wherein said adenovirus comprises the gene of interest.
A method of transducing a cell and expressing a gene of interest, comprising exposing said cell to an adenovirus comprising a fiber of an adenovirus of subgenus D, or part thereof, wherein said virus is capable of infecting said cell, and wherein said adenovirus comprises the gene of interest.
A method of vaccinating an animal or human against an infectious agent or a tumor antigen, comprising transducing a dendritic cell of said animal or human by exposure to an effective amount of an adenovirus comprising a fiber of an adenovirus of subgenus D, or part thereof.
Dependencies are inferred from the claim text.